A Phase Ib Safety Run-In And Randomized Phase II, Open-Label Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of M6620 In Combination With Avelumab And Carboplatin In Comparison To Standard Of Care Therapy In Participants With Parpi-Resistant Recurrent Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer